Quantcast

Latest Deep brain stimulation Stories

2011-05-26 07:05:00

FORT LEE, N.J., May 26, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX) announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD). Improvements in the Unified Parkinson's Disease Rating Scale (UPDRS) at 12 months for the randomized, double-blind, sham surgery-controlled trial of 45...

2011-04-28 19:07:00

LOS ANGELES, April 28, 2011 /PRNewswire/ -- This afternoon, at the Antiepileptic Drug Trials XI Conference in Miami, Florida, (http://www.epilepsy.com/etp/aedtrialxi) Dr. Christopher DeGiorgio, principal investigator and neurologist at UCLA, presented the results of a Phase II randomized double-blind clinical trial for the treatment of refractory epilepsy. The 50-subject study was conducted at UCLA and the University of Southern California. "I'm excited to see that our non-invasive and...

2011-04-25 08:44:00

LOS ANGELES, April 25, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced research progress on three therapies employing trigeminal nerve stimulation (TNS), originally developed at UCLA and exclusively licensed to NeuroSigma. Background - TNS NeuroSigma is developing two embodiments of TNS: eTNS(TM) (TNS with external electrodes and an external pulse generator) and sTNS(TM) (subcutaneous electrodes and implantable pulse generator). The...

2011-04-07 16:02:03

Medications lose effectiveness for many with longstanding tremors, study finds Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report. "It's a significant finding demonstrating that patients see a lot of symptom improvement with this treatment option," said Andrew Resnick, a research assistant...

2011-04-04 05:00:00

LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign. "We look forward to working closely with CCG to establish and enhance our profile in the investment community...

2011-03-30 15:51:40

The first two stereo-EEG explorations in Finland were carried out by neurosurgeons of the Epilepsy surgery team in Helsinki University Central Hospital this spring. The method reinforces other examination methods already in use and opens an excellent opportunity in the exploration of the electric activity of both the surface and the deep brain structures during epileptic seizures. The examination also enables exact localization of the functionally important areas of the brain and improves...

2011-03-17 12:34:36

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery. "The study demonstrates that the promise of gene therapy for neurodegenerative disorders has become a reality," says study lead author and co-principal investigator Peter LeWitt, M.D., director of movement disorders at Henry Ford Health System. The new study is...

2011-03-17 12:32:49

Results from the first successful phase 2 clinical trial of gene therapy for Parkinson's or any neurologic disorder A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling. The study is the first successful randomized, double-blind clinical trial of a gene therapy for Parkinson's or any...

2011-03-16 17:30:00

DETROIT, March 16, 2011 /PRNewswire/ -- A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery. "The study demonstrates that the promise of gene therapy for neurodegenerative disorders has become a reality," says study lead author and co-principal investigator Peter LeWitt, M.D., director of movement disorders at...

2011-03-16 17:30:00

FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) were published in an online-first edition of The Lancet Neurology. The randomized, double-blind, sham surgery-controlled trial of 45 subjects with advanced PD met its primary outcome measurement for efficacy and demonstrated that...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related